Biotechnology
WellmarkerBio receives approval for Phase I clinical trial from the Australian Therapeutic Goods Administration
SEOUL, South Korea, March 3, 2021 /PRNewswire/ -- Wellmarker Bio(www.wmbio.co
2021-03-03 22:00
1574
Biotheus Announces the Closing of a New Round of Financing co-led by General Atlantic and IDG Capital
ZHUHAI, China, March 2, 2021 /PRNewswire/ -- Biotheus has announced the successful completion of a fourth round of financing, co-led by General Atlantic, a leading global growth equity investor, and IDG Capital, a global leading investment firm. Other new investors include Kunlun Capital, CPE, an...
2021-03-03 11:37
1473
CMAB Biopharma Congratulates Partner Innovent Biologics on FDA Clearance of IND Application of its COVID-19 Antibody Project
SUZHOU, China, March 2, 2021 /PRNewswire/ -- CMAB Biopharma (Suzhou) Inc ("CMAB") congratulates its partner Innovent Biologics, Inc ("Innovent") (1801.HK) on the U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for its antibody candidate which ta...
2021-03-03 11:12
1231
CMAB Biopharma Congratulates QureBio on FDA Clearance of IND Application for Claudin18.2/PD-L1 Bispecific Antibody
SUZHOU, China, March 2, 2021 /PRNewswire/ -- Recently, CMAB Biopharma (Suzhou) Inc's ("CMAB") partner QureBio Ltd ("QureBio") has announced its innovative drug Q-1802 received United States Food and Drug Administration (FDA) clearance for an Investigational New Drug (IND) application. This applic...
2021-03-02 13:43
1326
China Biologic Announces Shareholders' Approval of Merger Agreement
BEIJING, March 1, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that, at an extraordinary general meeting (the "EGM") held today, the Company...
2021-03-01 21:00
9766
Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development
SUZHOU, China, March 1, 2021 /PRNewswire/ -- Suzhou Medilink Therapeutics Ltd. (Medilink), a global biotech company focusing on next-generation antibody-drug conjugate Research & development, announced the closing of a$50 million series A financing, to accelerate its innovative pipeline developme...
2021-03-01 19:50
4430
CARsgen Therapeutics Receives Orphan Medicinal Product Designation from the European Medicines Agency for CT041 CLDN18.2 CAR T Cells for the Treatment of Gastric Cancers
SHANGHAI, March 1, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited, a clinical-stage biopharmaceutical company, today announced that the European Commission (EC) has granted orphan designation for CT041, CARsgen's first-in-class Claudin 18.2 (CLDN18.2) targeted CAR-T product candidate ...
2021-03-01 19:00
3411
Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index
SHANGHAI and HONG KONG, Feb. 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...
2021-03-01 08:00
5647
Alterity to present at the 7th International Congress of Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th International Congress of Multiple System Atrophy (MSA2021), to be held in a virtual format fromFebruary 26-...
2021-02-26 20:45
6013
Biocytogen announces acquisition of a third Beacon Optofluidic system to support expanding Antibody Discovery Platform
BOSTON, Feb. 25, 2021 /PRNewswire/ -- Biocytogen, a company dedicated to accelerating therapeutic antibody discovery, has announced the acquisition of a third Beacon Optofluidic system. The new instrument, developed by Berkeley Lights, will support the expansion of Biocytogen's antibody discove...
2021-02-25 23:45
1552
Genome & Company and Debiopharm Join Forces To Create New Highly Specific Therapies for Cancer Patients
SEOUL, South Korea, Feb. 24, 2021 /PRNewswire/ -- Genome & Company (314130, CEO: Jisoo Pae, Hansoo Park), a global leading immuno-oncology firm, and Debiopharm, a Swiss-based biopharmaceutical company specializing in oncology and infectious diseases, today announced having entered into a research ...
2021-02-25 07:00
1956
Alternative meat startup Next Meats Co., Ltd and microalgae biotech company euglena Co., launch "NEXT Euglena Yakiniku EX" containing microalgae
TOKYO, Feb. 12, 2021 /PRNewswire/ -- Next Meats Co., LTD, the controlling shareholder of Next Meats Holdings, Inc. ("OTC: NXMH") announced that they had signed a joint product development agreement witheuglena Co., a biotech company also fromJapan which specializes in cultivating Euglena and Chlo...
2021-02-24 12:45
5355
GBB Completes USD$3.8M Convertible Note Financing Led by Alibaba Hong Kong Entrepreneurs Fund
HONG KONG, Feb. 23, 2021 /PRNewswire/ -- Great Bay Bio Holdings Limited (hereinafter referred to as "GBB") today announced it has completed aUSD$3.8M Convertible Note Financing. Alibaba Hong Kong Entrepreneurs Fund (hereinafter referred to as "AEF") led the investment round with participation fro...
2021-02-23 23:00
1881
ABclonal Biotechnology Completes $93 Million Series C Financing
WOBURN, Mass., Feb. 22, 2021 /PRNewswire/ -- ABclonal Biotechnology, a global life science tools and services provider, recently completed its$92.9 million Series C financing led by Sequoia Capital China and healthcare-focused investor LYFE Capital. Other new and existing shareholders, such as Si...
2021-02-22 20:00
1542
GenScript ProBio and Neoletix Announce Successful Completion of 200-Liter GMP Production Runs of Recombinant Coagulation FVIII Based on a Novel Production Technology
NANJING, China, Feb. 18, 2021 /PRNewswire/ -- On February 7th, 2021, GenScript ProBio announced that it has successfully completed 3 X 200 L GMP production runs of recombinant human factor VIII (rhFVIII) for Beijing Neoletix Biological Technology Co., Ltd. (Neoletix). InMay 2019, GenScript ProBio...
2021-02-18 22:00
1731
Bionic Vision Technologies Advances Clinical Program With AU$1 million Medical Research Future Fund Grant
MELBOURNE, Australia, Feb. 16, 2021 /PRNewswire/ -- Bionic Vision Technologies (BVT) has started work on the next phase of development for its world-leading Australian bionic eye technology thanks to a recent Australian Government grant to refine its vision processing algorithms. BVT's bionic ey...
2021-02-17 08:03
1216
Transcenta Holding Announces Appointment of Dr. Michael Shi as Executive Vice President, Head of Global R&D and Chief Medical Officer
SUZHOU, China, Feb. 10, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the appointment of Dr.Michael Shi as Executive Vic...
2021-02-11 08:00
1586
Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials
NEW YORK, Feb. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the award of a grant from The Michael J. Fox Foundation for Parkinson's Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson's di...
2021-02-09 21:53
3283
Neurophth Closes RMB 400 Million Series B Financing
Proceeds to support – * continued development of robust portfolio of AAV-delivered therapeutics with IND initiation of ND4-mediated LHON planned in 2021 * completion of Suzhou GMP manufacturing facility in accordance with the international quality standards planned in 2021 * initiation of ...
2021-02-09 21:44
1861
Experiment showed that Jemincare's neutralizing antibody JMB2002 would likely keep the potency against the South African mutant
SHANGHAI, Feb. 8, 2021 /PRNewswire/ -- On February 7, 2021, scientists from Jemincare Shanghai Research Institute published a preprint paper on BioRxiv, the paper entitled "A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prop...
2021-02-09 11:18
1258
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
[Picked up by 295 media titles]
2024-04-12 15:14
LEGOLAND® School Challenge 2024 Expands Across Asia and Opens for Registration on April 15th
[Picked up by 276 media titles]
2024-04-11 11:00
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
[Picked up by 275 media titles]
2024-04-15 08:00
Most Read
LEGOLAND® School Challenge 2024 Expands Across Asia and Opens for Registration on April 15th
2024-04-11 11:00
6692
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
2024-04-12 15:14
6398
XCMG Machinery Launches Premium G2 Crane Brand
2024-04-12 14:39
6330
